<DOC>
	<DOC>NCT00385203</DOC>
	<brief_summary>To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy) and also in patients with metastatic Soft Tissue Sarcoma (STS) resistant to standard therapy.</brief_summary>
	<brief_title>The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Histological or cytological confirmation of GIST which is resistant or intolerant to imatinib mesylate, or metastatic STS, which is refractory to standard therapies or for which no standard therapy exists Patients with type I insulindependent diabetes or poorlycontrolled type II insulinindependent diabetes. Patients with a history of poorly controlled high blood pressure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumour</keyword>
	<keyword>advanced cancer</keyword>
	<keyword>Metastatic Gastro-Intestinal Stromal Tumours</keyword>
	<keyword>gastro-intestinal cancer</keyword>
	<keyword>RECENTIN</keyword>
</DOC>